Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.

Small cell lung cancer (SCLC), ... The modest efficacy of immune checkpoint inhibitors (ICIs) in SCLC contrasts sharply with their success in non-small cell lung cancer ... Badura ML, Lee F, Bidkar AP ...

Adventist Health Ukiah Valley recently unveiled its new PET/CT machine, which will offer faster results and peace of mind for ...

Each year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with ...

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial. Contact Us. Contact Us. ... “We confirmed this response with a second scan, ...

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, making up about 80 to 85 percent of all cases. [ 1 ] It’s referred to as metastatic NSCLC when it has spread from the ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment of small cell lung cancer (SCLC), a practice-changing phase III trial ...

Tip Sheet: A new treatment for metastatic colorectal cancer, discoveries for small cell lung cancer — and a state-of-the-art learning lab for community education SEATTLE — June 4, 2025 — Below are ...

PD-1/IL-2 α-bias bispecific antibody fusion protein IBI363 in patients with immunotherapy resistant advanced non-small cell lung cancer: results from a Phase 1 study.